Therapeutics & Vaccines
Synthesis of Novel Small Molecule CARM1 Degraders, Compounds Formed Thereby, and Pharmaceutical Compositions Containing Them
WARF: P230336US02
Inventors: Weiping Tang, Wei Xu, Haibo Xie, Megan Bacabac
The Invention
UW-Madison researchers have developed a focused library of CARM1 protein degraders. These degraders used a known binding molecule of CARM1 with an optimized linker attached to a Von Hippel–Lindau (VHL) ligand that recruits a ubiquitin ligase to CARM1. Upon ubiquitination, the cell removes CARM1 protein. They showed that their lead molecule can selectively degrade CARM1. The degradation of the protein leads to a reduction in mobility of triple negative breast cancer cells.
Â
There didn’t appear to be any effect on cell growth or proliferation. More work will need to be done to determine whether degradation of CARM1 is a validated cancer therapeutic strategy.
Additional Information
For More Information About the Inventors
Tech Fields
For current licensing status, please contact Rafael Diaz at [javascript protected email address] or 608-960-9847